Lexaria’s Registered GLP-1 Study #4 Begins Dosing

Lexaria’s Registered GLP-1 Study #4 Begins Dosing Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss Kelowna, British Columbia – December 19, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has begun dosing in the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4, (the “Study”). The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH

Read the full article here

Source: mailchi.mp

Categories: Expert Picks, General Medicine News

Tags: Lexaria,GLP

Tweets with this article

C. Michael Gibson MD

#Lexaria has begun dosing in a Phase 1b study to determine whether Lexaria’s proprietary DehydraTECH technology improves the safety and effectiveness of existing #GLP-1 drugs. COI I'm an advisor to the company. https://t.co/EhFWWkaBU4

Related Articles

Atrial Fibrillation

This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of atrial fibrillation, which is associated with increased rates of stroke, heart failure, and mortality,…

Eric Topol December 26, 2024

Deep Learning Model for Predicting Immunotherapy Response in Advanced NSCLC

This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small…

Eric Topol December 26, 2024

Human Thought Is Far Slower Than Your Internet Connection (Gift Article)

A new study is “a bit of a counterweight to the endless hyperbole about how incredibly complex and powerful the human brain is,” one researcher…

Eric Topol December 26, 2024

Interventions for the management of long covid (post-covid condition): living systematic review

Objective To compare the effectiveness of interventions for the management of long covid (post-covid condition). Design Living systematic review. Data sources Medline, Embase, CINAHL, PsycInfo,…

Eric Topol December 26, 2024

Tips on taking care of your skin during cold weather

Your skin deserves some extra love this winter! Tune in to this @9news segment as I share tips to protect and nourish your skin during…

Payal Kohli,MD,FACC December 25, 2024

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor…

Dr. Martha Gulati December 24, 2024

Prediction of metabolic subphenotypes of type 2 diabetes via continuous glucose monitoring and machine learning

Nature Biomedical Engineering – Metabolic subphenotypes of type 2 diabetes can be predicted by the shape of the glucose curve measured via a continuous glucose…

Eric Topol December 24, 2024

Trial reveals anti-inflammatory power of aerobic exercise in adults with obesity

New research presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12–15 May), reveals the anti-inflammatory power of moderate-to-vigorous aerobic exercise in…

Eric Topol December 24, 2024

Heart health and the holidays: Medical expert weighs in

Did you know heart attack risk spikes during the holiday season? I am on @9news to discuss heart attack risk during the holidays, and ways…

Payal Kohli,MD,FACC December 24, 2024

Empowering biomedical discovery with AI agents

By combining human creativity and subject expertise with the power and potential of artificial intelligence, “AI systems” will help enable powerful discoveries across the biomedical…

Eric Topol December 23, 2024